UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1393-3
Program Prior Authorization/Notification
Medication Hyftor® (sirolimus topical gel)
P&T Approval Date 9/2022, 9/2023, 9/2024
Effective Date 12/1/2024
1. Background:
Hyftor (sirolimus topical gel) is an mTOR (mechanistic target of rapamycin) inhibitor
immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous
sclerosis in adults and pediatric patients 6 years of age and older.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Hyftor will be approved based on both of the following criteria:
a. Diagnosis of tuberous sclerosis
-AND-
b. Patient has facial angiofibroma associated with tuberous sclerosis
Authorization will be issued for 12 months.
B. Reauthorization
1. Hyftor will be approved based upon the following criterion:
a. Documentation of positive clinical response to therapy (e.g., improvement in skin
lesions)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits, Medical Necessity, and/or Step Therapy may be in place.
© 2024 UnitedHealthcare Services, Inc.
1
4. References:
1. Hyftor [package insert]. Bethesda, MD: Nobelpharma America, LLC; March 2022.
Program Prior Authorization/Notification - Hyftor® (sirolimus topical gel)
Change Control
9/2022 New program.
9/2023 Annual review with no change to coverage criteria.
9/2024 Annual review. Updated initial authorization to 12 months.
© 2024 UnitedHealthcare Services, Inc.
2